RU2404795C2 - Способы лечения почечно-клеточной карциномы - Google Patents

Способы лечения почечно-клеточной карциномы Download PDF

Info

Publication number
RU2404795C2
RU2404795C2 RU2007132125/14A RU2007132125A RU2404795C2 RU 2404795 C2 RU2404795 C2 RU 2404795C2 RU 2007132125/14 A RU2007132125/14 A RU 2007132125/14A RU 2007132125 A RU2007132125 A RU 2007132125A RU 2404795 C2 RU2404795 C2 RU 2404795C2
Authority
RU
Russia
Prior art keywords
des
mutein
amino acid
sequence
weeks
Prior art date
Application number
RU2007132125/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007132125A (ru
Inventor
Лоренс ЭЛИАС (US)
Лоренс Элиас
Гэри ВАЙТРЕЛЛ (US)
Гэри ВАЙТРЕЛЛ
Original Assignee
Новартис Вэксинс Энд Диагностикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Вэксинс Энд Диагностикс Инк. filed Critical Новартис Вэксинс Энд Диагностикс Инк.
Publication of RU2007132125A publication Critical patent/RU2007132125A/ru
Application granted granted Critical
Publication of RU2404795C2 publication Critical patent/RU2404795C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2007132125/14A 2005-01-27 2006-01-27 Способы лечения почечно-клеточной карциномы RU2404795C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
US60/647,496 2005-01-27

Publications (2)

Publication Number Publication Date
RU2007132125A RU2007132125A (ru) 2009-03-10
RU2404795C2 true RU2404795C2 (ru) 2010-11-27

Family

ID=36741121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007132125/14A RU2404795C2 (ru) 2005-01-27 2006-01-27 Способы лечения почечно-клеточной карциномы

Country Status (13)

Country Link
US (2) US20070014765A1 (https=)
EP (1) EP1846020B1 (https=)
JP (2) JP2008528621A (https=)
KR (1) KR20070102576A (https=)
CN (1) CN101132809A (https=)
AU (1) AU2006207987B2 (https=)
BR (1) BRPI0606774A2 (https=)
CA (1) CA2595959A1 (https=)
ES (1) ES2432141T3 (https=)
IL (1) IL184865A (https=)
MX (1) MX2007009012A (https=)
RU (1) RU2404795C2 (https=)
WO (1) WO2006081510A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370399A4 (en) * 2008-12-11 2013-05-22 Agency Science Tech & Res GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
KR102220006B1 (ko) * 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
ES2811624T3 (es) * 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174409C2 (ru) * 1995-11-30 2001-10-10 Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем Способы и композиции для диагностики и лечения рака
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174409C2 (ru) * 1995-11-30 2001-10-10 Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем Способы и композиции для диагностики и лечения рака
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMATO R.J., SCHELL J. et al: Phase II study of thalidomide+interleukm-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc ASCO 22:387, (abstr #1556), 2003. VERRA N. et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma., Br J Cancer. 2003 May 6; 88(9): 1346-1351. *
SLEIJFER D.T. et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced., J Clin OncoL, 1992; 10: 1119-1123. *

Also Published As

Publication number Publication date
JP2008528621A (ja) 2008-07-31
MX2007009012A (es) 2007-09-14
WO2006081510A2 (en) 2006-08-03
AU2006207987B2 (en) 2011-09-15
EP1846020A2 (en) 2007-10-24
RU2007132125A (ru) 2009-03-10
US20100316595A1 (en) 2010-12-16
BRPI0606774A2 (pt) 2009-07-14
CA2595959A1 (en) 2006-08-03
WO2006081510A3 (en) 2007-01-18
IL184865A (en) 2011-04-28
IL184865A0 (en) 2007-12-03
JP2012046552A (ja) 2012-03-08
AU2006207987A1 (en) 2006-08-03
ES2432141T3 (es) 2013-11-29
CN101132809A (zh) 2008-02-27
EP1846020B1 (en) 2013-08-21
US20070014765A1 (en) 2007-01-18
US8012465B2 (en) 2011-09-06
KR20070102576A (ko) 2007-10-18

Similar Documents

Publication Publication Date Title
RU2404795C2 (ru) Способы лечения почечно-клеточной карциномы
JP6718494B2 (ja) 癌を処置するためのペグ化ｉｌ−１０の使用
ES2906615T3 (es) Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
AU2010204552B2 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
AU2014208224A1 (en) New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein
KR20140130705A (ko) 체강액 저류 억제제
HK1172248A (en) Use of pegylated il-10 to treat cancer
HK1127553B (en) Use of pegylated il-10 to treat cancer
HK1201182B (en) Pegylated il-10 for use in treating lymphoma

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210128